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Despite the major advances in the management of HIV infection, HIV-infected patients still have greater morbidity
and mortality than the general population. Serious non-AIDS events (SNAEs), including non-AIDS malignancies,
cardiovascular events, renal and hepatic disease, bone disorders and neurocognitive impairment, have become the
major causes of morbidity and mortality in the antiretroviral therapy (ART) era. SNAEs occur at the rate of 1 to 2 per
100 person-years of follow-up. The pathogenesis of SNAEs is multifactorial and includes the direct effect of HIV and
associated immunodeficiency, underlying co-infections and co-morbidities, immune activation with associated
inflammation and coagulopathy as well as ART toxicities. A number of novel strategies such as ART intensification,
treatment of co-infection, the use of anti-inflammatory drugs and agents that reduce microbial translocation are
currently being examined for their potential effects in reducing immune activation and SNAEs. However, currently,
initiation of ART before advanced immunodeficiency, smoking cessation, optimisation of cardiovascular risk factors
and treatment of HCV infection are most strongly linked with reduced risk of SNAEs or mortality. Clinicians should
therefore focus their attention on addressing these issues prior to the availability of further data.
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Since the first description of AIDS in 1981, there have
been tremendous advances in understanding the biology
of the virus, the host’s immune response and the clinical
management of HIV infection. The introduction of com-
bination antiretroviral therapy (ART) in 1996 has revo-
lutionized HIV treatment, increasing the average life
expectancy after HIV diagnosis from 10.5 to 22.5 years
from 1996 to 2005 [1]. The estimated life expectancy for a
30 year old male infected with a drug-sensitive virus in
2010 and starting ART at about 6 years post infection can
be as high as 75 years in some predictive models [2].
Despite the success of ART, life expectancy in HIV-
infected patients is still lower than uninfected persons
[2-4] and mortality in HIV-infected patients can be up
to 15 times higher when compared with the general popu-
lation, matched for sex and age [3]. In the pre-ART era,
AIDS was the primary cause of death in HIV-infected pa-
tients [5-7]. With the use of ART, mortality due to serious* Correspondence: d.hsu@amr.org.au
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stated.non-AIDS events (SNAEs) has become more prominent
especially in resource-rich settings [6,8-13] and in patients
with higher CD4 T cell counts [7,14].Definition of serious non-AIDS events
Non-AIDS events (NAEs) are clinical events that do not
meet the definition of AIDS-defining events based on
the 1993 US Centers for Disease Control and Prevention
(CDC) AIDS indicator conditions [15]. They encompass
multiple diseases involving different organ systems, in-
cluding cardiovascular, liver and renal disease, non-
AIDS-defining malignancies, diabetes, neuropsychiatric
disorders and bone-related abnormalities [16].
SNAEs are NAEs that result in death, are life-threatening,
cause prolonged hospitalization and persistent incapacity or
are associated with significant morbidity [12,14,17]. Most
studies include cardiovascular, liver and end stage renal dis-
ease, as well as non-AIDS-defining cancers [11,14,18,19].
Other studies include an even broader range of conditions
such as non-AIDS-related infections and psychiatric events
[7,12,16,17,20].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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The incidence of SNAEs in ART-treated patients is
around 1 to 2 per 100 person-years of follow-up (PYFU)
[11,14,17-19,21], (Table 1), but can be up to 60 per 100
PYFU in a cohort of treatment-experienced patients with
multidrug resistant virus [12]. The relative contribution
of non-AIDS malignancy, cardiovascular, liver and end
stage renal disease to SNAEs vary across studies due to
inconsistencies in the definition of SNAEs and differences
in the rates of underlying co-morbidities e.g. Hepatitis B
virus (HBV) and Hepatitis C virus (HCV) co-infection.
However, non-AIDS malignancy, cardiovascular disease
(CVD) and liver disease combined seem to account for
>80% of SNAEs according to several published studies
[9,11,14,17,18]. The incidence of non-AIDS malignancy
and cardiovascular disease is about 2-fold higher in HIV-
infected patients in the ART era when compared to the
general population [22-26].
SNAEs are associated with worse outcome than AIDS
events in the ART era. Compared with ART-treated
patients without events, the risk of death is increased by
7 to 11-fold in those with SNAEs and by 4 to 5-fold in
those with AIDS events [11,14]. Amongst SNAEs, liver-
related events are associated with the highest mortality
[11,14], followed by renal events, malignancies and car-
diovascular events, with estimated 12-month mortality
of 39.7, 32.7, 29.5 and 6.1% respectively [11].
SNAEs pathogenesis
Prior to the Strategies for Management of Antiretroviral
Therapy (SMART) Study, ART toxicities were thought
to be a major contributor to SNAEs. In the SMART
Study, over 5000 HIV-infected patients with CD4 T cell
count >350 cells/μL were randomized to either episodic
ART (when CD4 T cell count fell below 250 cells/μL) or
continuous ART. Patients on episodic ART had 1.8-fold
increase in mortality and 1.7-fold increase in SNAEs
(defined as major cardiovascular, renal or hepatic disease)
when compared to those on continuous ART [27], thereby
highlighting the role of HIV viraemia and immunodefi-
ciency in the pathogenesis of SNAEs [28].
The pathogenesis of SNAEs is in fact multifactorial and
complex (Figure 1). The direct effect of HIV and associ-
ated immunodeficiency, underlying co-morbidities and
co-infections, immune activation with associated inflam-
mation and coagulopathy as well as ART toxicities can all
contribute.
The direct effect of HIV
Uncontrolled HIV replication causes immune activation
and progressive decline in CD4 T cell count [29]. In
addition, HIV can also contribute directly to organ
dysfunction and SNAEs. HIV can infect human hepatic
stellate cells and induce collagen expression and pro-inflammatory cytokines secretion in vitro [30,31]. HIV
can also mediate dysregulation of glomerular podocytes
in HIV-transgenic mouse models [32], as well as apop-
tosis of human renal tubular cell lines [33]. Therefore,
direct effect of HIV may contribute to decline in renal
function and increase risk of chronic kidney disease [34].
HIV may contribute directly to non-AIDS malignancy
[35], as it can be oncogenic by activating proto-onco-
genes [36] or by blocking tumour suppressor genes [37]
in cell lines. Increased rates of microsatellite instability
in tumours of HIV-infected patients have also been
found [38].
Immunodeficiency
Lower nadir or pre-ART CD4 T cell count is associated
with increased risk of SNAEs [11,14,16,39]. In addition,
the degree of CD4 T cell recovery after ART initiation
also influences the incidence of SNAEs [14,18,21,39]. A
100 cells/μL lower latest CD4 T cell count in ART-
treated patients is associated with a 30% increase in the
risk of SNAEs, even after adjusting for smoking status,
diabetes mellitus, hyperlipidaemia, HCV and HBV co-
infection and alcohol abuse [18]. Lower latest CD4 T cell
count in ART-treated patients is also associated with an
increase in mortality [40,41].
Suboptimal restoration of CD4 T cells may be secondary
to a number of factors including decreased thymic
function [42,43] and impaired homeostatic responses and
survival of T cells [44]. HIV replication and immune
activation stimulate the secretion of transforming growth
factor (TGF-β), mainly by regulatory T cells, with macro-
phages also contributing. TGF-β triggers collagen produc-
tion by fibroblasts [45-47]. The resultant structural
damage and fibrosis of the lymphoid tissues restricts T cell
access to interleukin-7 (IL-7) on the fibroblastic reticular
cell (FRC) network [45] thus limiting naïve CD4 T cell
survival [48,49]. Furthermore, ongoing immune activation
leads to rapid CD4 T cell turnover, overwhelming the
already impaired renewal mechanisms [44], resulting in
suboptimal CD4 recovery [50,51].
Co-infections
Due to common routes of transmission, HIV-infected
patients also have increased risk of exposure to other
infections that can cause organ dysfunction.
About 6-14% of HIV-infected patients have HBV and
about 25-30% have HCV infection, with the rates varying
depending on endemicity of HBV in the population and
the prevalence of injecting drug use [52]. HBV and/or
HCV co-infection greatly increases the risk of SNAEs
despite ART [9,11,14,18,39,53]. Co-infection with HCV is
associated with increased risk of renal disease (1.5-fold)
[54,55], cardiovascular disease (1.5-fold) [56], cirrhosis
(19-fold) and hepatocellular carcinoma (5-fold) [57]
Table 1 Summary of studies describing the incidence of SNAEs in various patient populations


















EuroSIDA A prospective observational cohort of HIV-infected
patients in Europe, Israel and Argentina followed
from 2001-09.
12844 73 39 178 403 6 24 1.8 [14]
SMART (S)
ESPRIT(E)
S: HIV-infected patients with CD4 count >350 cells/μL
were randomized to either CD4 count guided episodic
use of ART or to continuous use of ART. E: HIV-infected
patients with CD4 count >300 cells/μL were randomized







S: 43 E: 40 S: 250 E: 197 S: 597 E: 457 S: 2 S: 15 1 [11,27,127]
An observational cohort of HIV-infected patients with CD4
count >500 cells/μL in Spain from 1996-2011.
547 10 80 43 348 630 5 28 1.4 [17]
CoRIS A prospective multicenter observational cohort of
HIV-infected patients in Spain followed from 2004-2010.
5185 2.1 79 36 342 4 12 2.9 [16]
A retrospective study of HIV-infected patients receiving
ART in Botswana (B) and Nashville, USA (US); from









B: 199 US: 243 B: 1 US: 1.2 [19]
LATINA A retrospective study of HIV-infected patients in
Latin America from 1997-2007.
6007 2.5 70 0.9 [18]
APROCO/
COPILOTE
A prospective observational cohort of HIV-infected
patients in France followed from 1997-2006.
1231 7.3 77 36 279 5 23 10.5 [20]
OPTIMA HIV-infected patients with resistance to at least 2
different multidrug regimens were randomized to
(a) re-treatment with either standard (≤4) or
intensive (≥5) antiretroviral drugs and (b) either
treatment starting immediately or after a 12-week
monitored ART interruption.
368 4 98 48 107 11 22 61.0 [12]
ATHENA An observational cohort of ART naive HIV-infected
patients starting ART in the Netherlands, 1996-2010.




















Figure 1 Pathogenesis of serious non-AIDS events. HIV infection causes progressive decline in CD4 T cells through direct cytopathic effects
and immune mediated killing of infected cells, as well as indirectly via immune activation. Other drivers of immune activation include
co-infections and microbial translocation. HIV can contribute to organ dysfunction through detrimental effects on hepatic stellate cells and renal
tubular cells. HIV may also be oncogenic. Co-infection with HBV and HCV is especially important in liver related events. In addition, patients’
underlying co-morbidities e.g. smoking, cardiovascular risk factors, and ART related toxicities also contribute to SNAEs.
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the ART era.
HIV-infected patients also have increased risk of
exposure to Human papillomavirus (HPV) [58], that is
implicated in the pathogenesis of cervical and anal
cancer [59,60].
Other co-morbidities
HIV-infected patients also have higher prevalence of
traditional cardiovascular risk factors such as smoking
[61-63], elevated total cholesterol/HDL ratio [61-64] and
substance abuse [65]. Some studies also found higher
rates of hypertension and diabetes [64,66], but these
findings have not been confirmed by others [62,63,67].
Smoking is a major cause of increased mortality in
ART-treated patients, accounting for a loss of >12 life
years, and is associated with >4-fold increase in all-cause
mortality, >5-fold increase in non-AIDS mortality, >4-
fold increase in cardiovascular-related mortality and >3-
fold increase in cancer-related mortality [68].
Though uncontrolled HIV replication, immunodefi-
ciency, co-infection and co-morbid conditions are im-
portant contributors to the pathogenesis of SNAEs,
these factors only partially account for the increased risk
of SNAEs in HIV-infected patients. HIV elite controllers
have increased coronary plaques and carotid intima
media thickness when compared to uninfected controls
even after adjustment for traditional cardiovascular risk
factors [69,70], demonstrating that factors other than
uncontrolled viral replication, immunodeficiency, trad-
itional risk factors, and ART toxicities contribute to
increased cardiovascular risks in HIV-infected patients.Immune activation
Inflammation is central to the process of atherosclerosis
[71,72], tumour progression [73,74] and liver fibrosis
[75,76] in the general population. High levels of biomar-
kers associated with inflammation (C-reactive protein,
CRP, and IL-6) and coagulopathy (D-dimer and fibrino-
gen) are associated with increased risk of cardiovascular
disease [77-80], increased cancer risks [81-83] and mortal-
ity [80,84-86] in the general population.
In HIV-infected patients, CRP, IL-6 and D-dimer levels
[61] as well as markers of T cell activation [50,87]
remain higher than uninfected controls despite suppres-
sive ART. Furthermore, higher CRP, IL-6 and D-dimer
[88-90], soluble CD14 (sCD14, a marker of LPS-induced
monocyte activation) [91] and lymphocyte activation
markers [92] are associated with higher mortality.
In ART-treated patients, CRP, IL-6 and D-dimer levels
are also associated with increased risk of CVD, in-
dependent of other CVD risk factors [93,94]. These mar-
kers are also associated with increased risks of both
infection-related and infection unrelated cancers even
after adjusting for demographics and CD4 T cell count
[95]. Recently, higher levels of tumour necrosis factor
(TNF) were also found to be significantly associated with
increased risk of SNAEs [96]. Therefore these data sug-
gest that immune activation plays a very important role
in SNAEs pathogenesis.
Intermittent viraemia
The drivers of immune activation are diverse. Intermit-
tent HIV viraemia can occur in 20-30% of ART-treated
patients [97,98]. The presence of viraemia whilst on
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levels [62] and SNAEs [11,39]. In addition, viraemia
below the limit of detection of conventional assays also
correlates with persistent T cell activation [99]. There-
fore, residual viraemia may partially be responsible for
persistent immune activation despite ART.
Co-infections
The presence of co-infections also contributes to contin-
ual stimulation and activation of the immune system.
Asymptomatic CMV infection has been associated with
CD8 T cell activation in ART-treated patients [100].
CMV specific CD4 T cells can cause a systemic inflam-
matory response that is sustained even during latent
infection [101] and is associated with atherogenesis
[102,103]. Hepatitis C co-infection is also associated
with increased CD8 T cell activation when compared
with HIV mono-infected patients despite ART [104,105].
Microbial translocation
Microbial translocation due to impaired mucosal barrier
integrity may be another cause of immune activation in
HIV infection. Rhesus macaques with chronic SIV infec-
tion have disruptions of the epithelial barrier of the
colon and increased lipopolysaccharide (LPS) staining.
The levels of LPS staining in the colon also correlated
with the levels of LPS in the draining lymph nodes and
remote peripheral lymph nodes [106]. African green
monkeys are natural hosts of SIV. In chronic SIV infec-
tion, they display little immune activation, maintain
mucosal barrier integrity and do not progress to AIDS
[107]. However, the injection of LPS into SIV-infected
African green monkeys was associated with increases in
T cell activation, sCD14 and SIV viraemia [108]. In HIV-
infected patients, plasma LPS also correlated with
plasma interferon (IFN)-α and T cell activation levels
[109]. These data suggest that impaired mucosal barrier
integrity and microbial translocation may induce im-
mune activation.
Markers of microbial translocation e.g. LPS, sCD14
[110] and bacterial 16 s rDNA [111] do not always
normalise with ART. LPS can induce tissue factor ex-
pression on monocytes [112]. Tissue factor is the initi-
ator of the coagulation cascade [113] and its expression
on monocytes is correlated with D-dimer levels [112];
suggesting that microbial translocation may contribute
to atherogenesis and increased CVD [112].
Antiretroviral therapy
Finally, adverse effects of ART may also contribute to
SNAEs. A detail review of ART-related toxicities is
beyond the scope of this review. Protease inhibitors as a
class, as well as indinavir, lopinavir and abacavir may be
associated with increased risk of CVD [25,114,115].Some studies found that the rate of liver-related deaths
is increased per year of ART [116,117]. The cohort
described by Weber et al have high rates of HBV and
HCV infection, 17% and 66%, respectively [116]. Though
patients with HBV or HCV infection have about 5-
fold greater risk of hepatotoxicity after ART initiation
[118-120], ART is essential as it slows fibrosis pro-
gression [121] and reduces liver-related mortality by
about 10-fold [122]. In patients without chronic viral
hepatitis, ART toxicity rarely causes liver-related mortal-
ity, at a rate of 0.04 per 1000 person years [123].
ART has been associated with improved renal function
and a slower rate of eGFR decline in HIV-infected pa-
tients [124,125]. Though tenofovir use is associated with
higher risk of acute renal injury and greater loss of renal
function than other ART regimen, the overall risk of
serious renal event is not high, in 0.5% of patients [126].
Interventions to reduce SNAEs
Strategies to reduce SNAEs include preventing and revers-
ing immunodeficiency, the modification of traditional risk
factors, treatment of co-infections and addressing drivers
of immune activation. A wide variety of agents are cur-
rently being examined for their potential effects in redu-
cing immune activation and SNAEs (Table 2). However,
the majority of studies that have been performed are
small, are heterogeneous in terms of ART status and show
conflicting findings. The majority of studies used markers
of immune activation, in particular CD8 T cell activation
as outcome measures. Some recent studies have also
included sCD14 and D-dimer. However, randomized
placebo-controlled trials that use clinical outcome mea-
sures are rare [127].
Preventing and reversing immunodeficiency
ART initiation prior to advanced immunodeficiency
Data from randomized controlled trials suggest that defer-
ral of ART initiation until CD4 T cell count <250 cells/μL
was associated with increased SNAEs, AIDS-related
events and mortality [128-130]. Observational studies sug-
gest that ART initiation at CD4 T cell count >350 cells/μL
is associated with lower risk of SNAEs [14], AIDS-
defining illness or death when compared to deferring ART
[131-134]. The benefit of ART initiation at CD4 T cell
count >350 cells/μL when compared to deferring until
CD4 T cell count ~350 cells/μL is insignificant in some
studies when the analysis is restricted to mortality alone
[131,134]. Results from the START study (NCT00867048),
a multicenter international trial designed to assess the
risks and benefits of initiating ART at CD4 T cell count
at >500 or <350 cells/μL will likely shed further light on
this issue. Nonetheless, given that the majority of HIV-
infected patients start ART with CD4 T cell count <250
cells/μL [135,136], earlier HIV diagnosis and initiation
Table 2 Potential strategies to reduce SNAEs
Potential strategies to reduce SNAEs Interventions investigated or under evaluation References
Preventing immunodeficiency Initiate ART prior to advanced immunodeficiency [14,128-134]
Increasing CD4 T cell recovery
Cytokine therapy Subcutaneous IL-2 [127]
Subcutaneous IL-7 [137,138]
Modulating lymphoid tissue fibrosis Pirfenidone Human data pending
Angiotensin receptor antagonist Human data pending
ACE inhibitor Human data pending
Managing co-morbidities Smoking cessation [68,145]
Optimise blood pressure, lipids and diabetic control [146,147]
ART switch [152-160]
Reducing chronic antigen stimulation
Residual viraemia Raltegravir intensification [161-170]
Maraviroc intensification [171-174]
HBV and HCV co-infection Hepatitis B and C treatment [105,175,176]
CMV co-infection Valganciclovir [178]
HSV co-infection Valacyclovir [179]
Reducing inflammation Statins [182-187]
COX-2 inhibitors [195,196]
Aspirin [199]




Balancing microbiota Prebiotic, probiotic and synbiotic [210-213]
Reducing bacterial/endotoxin load Rifaximin Human data pending
Bovine colostrum [167]
Sevelamer Human data pending
Improving mucosal integrity Lubiprostone Human data pending
Reducing inflammation in the gut Mesalamine Human data pending
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reduce SNAEs.
Improving CD4 T cell recovery
A number of studies have investigated the use of cytokines
critical for T cell homeostasis e.g. IL-2 and IL-7 to
enhance CD4 T cell recovery. Though subcutaneous IL-2
administration in concert with ART resulted in sustained
increase in CD4 T cell count, this did not translate into
clinical benefit [127]. Subcutaneous IL-7 administration
also leads to increase in CD4 T cells in phase I and II stud-
ies [137,138] but clinical outcomes have not yet been
assessed. The restoration of TH17 cells and improvement
in TH17/T regulatory cell ratio may be especially import-
ant given their roles in mucosal immunity [139,140].Modulating the effects of lymphoid tissue fibrosis
Lymphoid tissue fibrosis is associated with poor CD4
T cell restoration after ART initiation [49]. TGF-β is
key in the process of lymphoid tissue fibrosis. Pirfeni-
done can reduce TGF-β production and has anti-
fibrotic effects [45,141]. Pirfenidone administered to
rhesus macaques prior to SIV infection was associated
with reduced lymph node fibrosis and preservation of
lymph node CD4 T cells [142]. TNF blockade with
adalimumab was also associated with attenuated TGF-
β expression, reduced lymph node fibrosis and preser-
ved lymph node architecture in a recent rhesus macaque
study [47]. The effect of pirfenidione or adalimumab on
lymph node fibrosis in HIV infection has not been studied
to date.
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renal and liver fibrosis. Binding of angiotensin II to the
angiotensin 1 receptor on cardiac fibroblast, hepatic stellate
cells or mesangial cells leads to proliferation as well as col-
lagen and TGF-β synthesis [143,144]. Trials on the effect
of angiotensin converting enzyme (ACE) inhibitor e.g. lisi-
nopril (ClinicalTrials.gov identifier: NCT01535235), angio-
tensin II receptor antagonists e.g. losartan (NCT01852942,
NCT01529749) and telmisartan (NCT01928927) in modu-
lating lymphoid tissue fibrosis are currently underway.
Optimizing cardiovascular risk factors
In the D.A.D study, patients who stopped smoking had
about 30% reduction in the risk of CVD [145]. Surpris-
ingly, a reduction in mortality was not seen. This may be
because patients ceased smoking after the diagnosis of a
serious illness and succumb before the benefit of smok-
ing cessation on mortality can be seen [145]. In the
Danish HIV cohort, previous smokers had a >1.5-fold
reduction in mortality when compared with current
smokers. In addition, though previous smokers have
higher rates of AIDS-related deaths when compared
with never smokers, the incidence of non-AIDS-related
death was not different between previous and never
smokers [68]. These data suggest that smoking cessation
alone would result in significant benefits and should be
encouraged.
Modification of other cardiovascular risk factors e.g.
treatment of hypertension, dyslipidaemia and optimal
glycaemic control in diabetic patients is critical. Sug-
gested target levels have been published [146,147]. Each
10 mmHg reduction in systolic blood pressure and each
38 mg/dL reduction in total cholesterol is associated
with a 5 and 20% reduction in risk of CVD, respectively
[148]. However, in patients with known hypertension,
diabetes or dyslipidaemia meeting indication for treat-
ment, over 40% were not on treatment [149]. Given that
a significant proportion of SNAEs are cardiovascular
events, more aggressive detection and management of
cardiovascular risk factors will likely reduce SNAEs.
ART modification is a potential strategy to reduce
cardiovascular risk [150]. A recent review of switch stud-
ies have been published [151]. Switching from stavudine
to tenofovir was associated with a reduction in total
cholesterol and triglycerides and an increase in limb fat
[152]. Switching from protease inhibitors to efavirenz or
nevirapine was associated with reduction in total cho-
lesterol [153]. However, this switch is not possible in
patients with non-nucleoside reverse transcriptase inhi-
bitor resistance. Switching from lopinavir/ritonavir to
atazanavir (both boosted with ritonavir 100 mg or
unboosted) was associated with reduction of total chol-
esterol and triglycerides, though greater reductions were
seen with unboosted atazanavir [154-156]. Switching toatazanavir was also associated with a reduction in car-
diovascular risk score [157]. Though switching from
lopinavir/ritonavir to raltegravir was associated with im-
provement in lipid profile [158,159], no change in endothe-
lial function was detected [160]. The importance of having
fully active backbone antiretrovirals was highlighted in the
SWITCHMRK study where patients switched to raltegra-
vir had higher rates of virologic failure [158].
Suppressing chronic antigen stimulation
Reducing residual viraemia
Intensification studies have been performed to assess the
impact of adding antiretroviral agents to a suppressive
ART regimen (as measured by conventional assays).
None of the raltegravir intensification studies were able
to demonstrate reduction in ultra-sensitive plasma HIV-
RNA levels [161-167]. In addition, the majority of
studies also found no reduction in markers of T cell
[161-164,167] or monocyte activation [167]. However,
some studies have noted a reduction in D-dimer levels
[168], T cell activation [165,166,169] as well as an early
transient increase in 2-LTR circles post raltegravir inten-
sification [168,170], suggesting that residual viraemia
was occurring prior to raltegravir intensification and was
contributing to immune activation in some patients.
Maraviroc intensification studies have also been per-
formed and yielded conflicting data. Some found reduc-
tion in T cell activation [171-173] whilst others found
increase in CD4 and CD8 T cell activation both in the
peripheral blood and in the rectal mucosa after mara-
viroc intensification [174]. Hunt et al postulated that the
binding of maraviroc to CCR5 prevents the interaction
between CCR5 and its natural ligands. Excess CCR5
ligands may then bind to other chemokine receptor such
as CCR3 and CCR4 on T cells, leading to T cell activa-
tion [174]. Therefore, the beneficial effect of adding anti-
retroviral agents to an already suppressive ART regimen
is uncertain based on currently available data.
Treating other co-infections
HCV treatment and suppression of HCV viraemia is
associated with reductions in CD4 and CD8 T cell acti-
vation [105]. Sustained virologic response is associated
with reduced liver-related complications as well as both
liver-related and non liver-related mortality in co-infected
patients [175,176]. Unfortunately, HCV treatment may be
limited by contraindications, adverse events, high costs,
and drug interactions. Next generation agents with higher
efficacy and better side effect profiles may revolutionise
the management of HIV/HCV co-infected patients [177].
Treatment of other persistent viral infection has also
been investigated. Eight weeks of valganciclovir in ART-
treated, CMV seropositive patients led to a significant
reduction of CMV viraemia as well as a reduction in CD8
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infection using 12 weeks of valacyclovir in ART-treated,
HSV-1 and HSV-2 seropositive patients, no change in T
cell activation, CRP or IL-6 levels was demonstrated [179].
Anti-inflammatory agents
Statins are 3-hydroxy-3-methyl-glutaryl-coenzyme A
reductase inhibitors. Not only do statins reduce serum
cholesterol [180], they may also have anti-inflammatory
properties [181]. Statin use is associated with reduced
monocyte activation (unpublished data McComsey et al),
decline in CRP levels [182] as well as reduced T cell
activation [183] in ART-treated and in untreated, HIV-
infected patients [184]. A retrospective observational
study of ART-treated patients showed that statin use is
associated with a 3-fold reduction in mortality [185].
Though not statistically significant, a trend for reduction
in SNAEs [186] and mortality [187] has also been seen in
other retrospective observational studies.
Hydroxychloroquine (HCQ) and its analogue chloro-
quine (CQ) have immunomodulatory, anti-inflammatory
and anti-HIV properties [188-190]. In patients with un-
controlled viral replication, the use of CQ was associated
with reduced CD8 T cell activation [191] whereas the
same effect was not seen with HCQ [192]. However a
non-randomized study of HCQ in 20 ART-treated pa-
tients showed decline in plasma LPS, IL-6 and reduced
T cell and monocyte activation [193]. Thus findings are
inconclusive.
COX-2 inhibitors inhibit cyclooxygenase type 2,
reducing Prostaglandin E2 production, thereby reducing
activation of T cells through the cyclic adenosine mono-
phosphate (cAMP) pathway [194]. Studies on COX-2
inhibitors have been small and reduction in T cell activa-
tion tended to occur in viraemic patients [195,196]. How-
ever, it is important to bear in mind that COX-2 inhibitors
are associated with increased cardiovascular risk, via a
direct pharmacologic consequence of inhibition of
COX-2 [197]. Therefore assessing the utility of COX-
2 inhibitors without using clinical outcome measures
may be insufficient.
Aspirin is a cornerstone in the secondary prevention
of vascular disease [198]. In a pilot study, aspirin use
was associated with reduced platelet activation, a de-
crease in sCD14 in monocytes and reductions in CD38
and HLA-DR on CD4 and CD8 T cells. However, there
was no change in IL-6, D-dimer and CRP [199]. An
aspirin study with larger number of participants is in
development with the AIDS Clinical Trials Group.
Leflunomide is an immunomodulatory agent that is
used in the treatment of rheumatoid arthritis. The ad-
ministration of leflunomide in untreated, HIV-infected
patients for 28 days was associated with a decrease in
CD8 T cell activation [200].The use of prednisone in patients with untreated
chronic HIV infection was associated with less CD4 T cell
depletion, a decline in CD4 T cell activation and stable
HIV viral load [201,202]. Prednisone at 0.5 mg/kg/day in
ART-treated patients was also associated with a reduction
in CD8 T cell activation and TNF levels as well as a transi-
ent decrease in IL-6 [203]. However, in another study
using prednisone at 40 mg/day, no reduction in CD4 or
CD8 T cell activation, plasma IL-6 or TNF levels was
found [204]. Furthermore, long-term prednisone use, es-
pecially at doses >7.5 mg/day is associated with significant
adverse effects such as osteoporosis, impaired glucose tol-
erance, dyslipidaemia, weight gain, cataract formation and
increased risk of infections [205]. Even short courses have
been associated with an increased risk of osteonecrosis
in HIV-infected patients [206].
Targeting microbial translocation
Given that HIV infection has been associated with
depressed levels of beneficial gut microbiota and elevated
levels of pathogenic microbiota [207], a range of prebiotics
(selectively fermented ingredients that changes the growth
and/or activity of certain gut microflora, resulting in
health benefits [208]), probiotics (live microorganisms that
when consumed, confer a health benefit [209]) and syn-
biotics (combinations of pre and probiotics) are under
investigation.
A prebiotic oligosaccharide mixture has been associ-
ated with improvement in microbiota composition and
reduction in sCD14 in untreated HIV-infected patients
[210]. A retrospective cohort study on both ART-treated
and untreated HIV-infected patients found that probiotic
yogurt consumption was associated with a greater
increase in CD4 T cell count even after adjustment for
ART [211]. A double-blind randomized placebo-con-
trolled trial in 20 untreated HIV-infected patients found
reductions in plasma bacterial DNA and IL-6 levels in
patients receiving synbiotics [212]. However, a synbiotic
agent in ART-treated women found no change in micro-
bial translocation nor immune activation status despite
improvement in the levels of probiotic species [213].
Therefore, more randomized controlled clinical trial data
are needed to clarify the effects of pre and probiotics in
reducing immune activation.
Bovine colostrum contains oligosaccharides, growth
factors, immunoglobulins and antimicrobial peptides
and has some activity in alleviating HIV-associated
diarrhoea in single arm studies [214-216]. However a
randomized controlled trial on the addition of bovine
colostrum to suppressive ART found no change in CD4
T cell count, markers of microbial translocation nor T
cell activation [167].
A number of new agents that target microbial trans-
location are under evaluation. Rifaximin is a minimally
Hsu et al. AIDS Research and Therapy 2013, 10:29 Page 9 of 15
http://www.aidsrestherapy.com/content/10/1/29absorbed oral rifamycin antibiotic that has activity
against both gram-positive and gram-negative enteric
bacteria [217]. It is effective in the treatment of hepatic
encephalopathy, by reducing ammonia-producing enteric
bacteria [218,219]. There are currently 3 clinical trials of
rifaximin in HIV-infected patients (ClinicalTrials.gov iden-
tifier: NCT01654939, NCT01866826 and NCT01466595).
Lubiprostone is a chloride channel activator that is used in
the treatment of constipation [220]. It has been found to
enhance recovery of mucosal barrier function in ischaemic
porcine colon [221]. A pilot study of lubiprostone in ART
treated, virologically suppressed patients with CD4 T cell
count <350 cells/μL (NCT01839734) is currently recruit-
ing. Sevelamer is a phosphate binder that is used in
patients with end-stage renal failure [222]. It can also bind
to endotoxins and reduce CRP, IL-6 and sCD14 in patients
on haemodialysis [223,224]. The trial in untreated, HIV-
infected patients (NCT01543958) was completed in June
2013 and results are pending. Mesalamine (5-aminosa-
licylic acid) is an anti-inflammatory agent used in the
management of inflammatory bowel disease [225]. A
trial using mesalamine in ART treated, virologically
suppressed patients with CD4 T cell count <350 cells/μL
(NCT01090102) is currently enrolling.
Conclusions
Despite the use of ART, HIV-infected patients still have
higher mortality and morbidity when compared to the
general population. SNAEs occur at the rate of about
1-2 per 100 PYFU and are the predominant causes of
morbidity and mortality in HIV-infected patients in the
ART era. Many factors contribute to the pathogenesis of
SNAEs including the direct effect of HIV and associated
immunodeficiency, underlying co-morbidities, immune
activation and ART toxicities. Though multiple interven-
tions have been investigated or are ongoing, most of the
studies are small, of short duration and clinical outcome
measures have not been ascertained. The cost required
to investigate the effectiveness of an intervention to
reduce SNAEs may be prohibitively high as it will re-
quire thousands of participants with possibly several
years of follow up.
Currently, the interventions with evidence to suggest
an association with reduced risk of SNAEs or mortality
are starting ART before advanced immunodeficiency,
smoking cessation, optimisation of cardiovascular risk
factors and treatment of HCV infection. Clinicians
should focus their attention on addressing these issues
prior to the availability of further data.
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